Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Amobarbital
Drug ID BADD_D00126
Description A barbiturate with hypnotic and sedative properties (but not antianxiety). Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmacopoeia, 30th ed, p565)
Indications and Usage Not Available
Marketing Status approved; illicit
ATC Code N05CA02
DrugBank ID DB01351
KEGG ID D00555
MeSH ID D000654
PubChem ID 2164
TTD Drug ID D0R6BR
NDC Product Code Not Available
UNII GWH6IJ239E
Synonyms Amobarbital | Amylobarbitone | Placidel | Amobarbital Sodium | Sodium, Amobarbital | Sodium Amobarbital | Amobarbital, Sodium | Amsal | Amylbarb sodium | Amylobeta | Amytal | Amytal Sodium | Sodium Amytal | Barbamyl | Eunoctal | Isoamitil Sedante | Isonal | Neur-Amyl | Novamobarb | Pentymal | Transital
Chemical Information
Molecular Formula C11H18N2O3
CAS Registry Number 57-43-2
SMILES CCC1(C(=O)NC(=O)NC1=O)CCC(C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Agitation17.02.05.012; 19.06.02.001--
Anaemia megaloblastic01.03.02.003; 14.12.01.003---
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.001---
Anxiety19.06.02.002--
Apnoea22.02.01.001--
Ataxia08.01.02.004; 17.02.02.001--
Atelectasis22.01.02.001--
Body temperature increased13.15.01.001---
Bradycardia02.03.02.002---
Completed suicide08.04.01.010; 19.12.01.001---
Confusional state17.02.03.005; 19.13.01.001--
Constipation07.02.02.001--
Depressed level of consciousness17.02.04.002--
Dermatitis23.03.04.002---
Dermatitis exfoliative10.01.01.004; 23.03.07.001--
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Erythema23.03.06.001---
Feeling abnormal08.01.09.014---
Hallucination19.10.04.003--
Headache17.14.01.001--
Hepatocellular injury09.01.07.008---
Hyperkinesia17.01.02.008---
Hypersensitivity10.01.03.003--
Hypotension24.06.03.002--
Hypoventilation22.02.01.007---
Hypoxia22.02.02.003--
Injection site reaction08.02.03.014; 12.07.03.015--
Loss of consciousness17.02.04.004---
Mental disability26.01.01.001---
Nausea07.01.07.001--
The 1th Page    1 2    Next   Last    Total 2 Pages